In vitro investigation of BK-218, a new oral and parenteral cephalosporin

I. Szabo, J. Barabas, A. Tar, L. Kiss, M. Filep, T. Schmidt, K. Marossy, B. Toth-Martinez, G. Barabas, F. Hernadi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The antibacterial activity of BK-218 was similar to that of cefamandole when it was tested against several laboratory strains. The inhibiting effect of BK-218 was greater than that of cephalexin and cefoxitin on penicillin-binding proteins of Escherichia coli HB101. This result was in close correlation with the relative inhibition of radiolabeled glucosamine incorporation (greatest with BK-218) and with the lytic effect (most intensive with BK-218). BK-218 proved to be a good inhibitor for all five of the β-lactamases that were investigated, although two enzymes (Enterobacter cloacae P99 and Pseudomonas aeruginosa Cilote) hydrolyzed it to some extent.

Original languageEnglish
Pages (from-to)349-354
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume34
Issue number2
Publication statusPublished - 1990

Fingerprint

Cephalosporins
Cefamandole
Penicillin-Binding Proteins
Cephalexin
Enterobacter cloacae
Cefoxitin
Glucosamine
Pseudomonas aeruginosa
In Vitro Techniques
BK 218
Escherichia coli
Enzymes

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Szabo, I., Barabas, J., Tar, A., Kiss, L., Filep, M., Schmidt, T., ... Hernadi, F. (1990). In vitro investigation of BK-218, a new oral and parenteral cephalosporin. Antimicrobial Agents and Chemotherapy, 34(2), 349-354.

In vitro investigation of BK-218, a new oral and parenteral cephalosporin. / Szabo, I.; Barabas, J.; Tar, A.; Kiss, L.; Filep, M.; Schmidt, T.; Marossy, K.; Toth-Martinez, B.; Barabas, G.; Hernadi, F.

In: Antimicrobial Agents and Chemotherapy, Vol. 34, No. 2, 1990, p. 349-354.

Research output: Contribution to journalArticle

Szabo, I, Barabas, J, Tar, A, Kiss, L, Filep, M, Schmidt, T, Marossy, K, Toth-Martinez, B, Barabas, G & Hernadi, F 1990, 'In vitro investigation of BK-218, a new oral and parenteral cephalosporin', Antimicrobial Agents and Chemotherapy, vol. 34, no. 2, pp. 349-354.
Szabo, I. ; Barabas, J. ; Tar, A. ; Kiss, L. ; Filep, M. ; Schmidt, T. ; Marossy, K. ; Toth-Martinez, B. ; Barabas, G. ; Hernadi, F. / In vitro investigation of BK-218, a new oral and parenteral cephalosporin. In: Antimicrobial Agents and Chemotherapy. 1990 ; Vol. 34, No. 2. pp. 349-354.
@article{b063bc39f1bd4c359b0ff79f663469a6,
title = "In vitro investigation of BK-218, a new oral and parenteral cephalosporin",
abstract = "The antibacterial activity of BK-218 was similar to that of cefamandole when it was tested against several laboratory strains. The inhibiting effect of BK-218 was greater than that of cephalexin and cefoxitin on penicillin-binding proteins of Escherichia coli HB101. This result was in close correlation with the relative inhibition of radiolabeled glucosamine incorporation (greatest with BK-218) and with the lytic effect (most intensive with BK-218). BK-218 proved to be a good inhibitor for all five of the β-lactamases that were investigated, although two enzymes (Enterobacter cloacae P99 and Pseudomonas aeruginosa Cilote) hydrolyzed it to some extent.",
author = "I. Szabo and J. Barabas and A. Tar and L. Kiss and M. Filep and T. Schmidt and K. Marossy and B. Toth-Martinez and G. Barabas and F. Hernadi",
year = "1990",
language = "English",
volume = "34",
pages = "349--354",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - In vitro investigation of BK-218, a new oral and parenteral cephalosporin

AU - Szabo, I.

AU - Barabas, J.

AU - Tar, A.

AU - Kiss, L.

AU - Filep, M.

AU - Schmidt, T.

AU - Marossy, K.

AU - Toth-Martinez, B.

AU - Barabas, G.

AU - Hernadi, F.

PY - 1990

Y1 - 1990

N2 - The antibacterial activity of BK-218 was similar to that of cefamandole when it was tested against several laboratory strains. The inhibiting effect of BK-218 was greater than that of cephalexin and cefoxitin on penicillin-binding proteins of Escherichia coli HB101. This result was in close correlation with the relative inhibition of radiolabeled glucosamine incorporation (greatest with BK-218) and with the lytic effect (most intensive with BK-218). BK-218 proved to be a good inhibitor for all five of the β-lactamases that were investigated, although two enzymes (Enterobacter cloacae P99 and Pseudomonas aeruginosa Cilote) hydrolyzed it to some extent.

AB - The antibacterial activity of BK-218 was similar to that of cefamandole when it was tested against several laboratory strains. The inhibiting effect of BK-218 was greater than that of cephalexin and cefoxitin on penicillin-binding proteins of Escherichia coli HB101. This result was in close correlation with the relative inhibition of radiolabeled glucosamine incorporation (greatest with BK-218) and with the lytic effect (most intensive with BK-218). BK-218 proved to be a good inhibitor for all five of the β-lactamases that were investigated, although two enzymes (Enterobacter cloacae P99 and Pseudomonas aeruginosa Cilote) hydrolyzed it to some extent.

UR - http://www.scopus.com/inward/record.url?scp=0025008892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025008892&partnerID=8YFLogxK

M3 - Article

C2 - 2109582

AN - SCOPUS:0025008892

VL - 34

SP - 349

EP - 354

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

ER -